Neuroimaging in Lewy body dementia

Research output: Contribution to journalReview articlepeer-review

49 Citations (Scopus)


Lewy body dementia (DLB) is a common form of cognitive impairment, accounting for 30% of dementia cases in ages over 65 years. Early diagnosis of DLB has been challenging; particularly in the context of differentiation with Parkinson's disease dementia and other forms of dementias, such as Alzheimer's disease and rapidly progressive dementias. Current practice involves the use of [123I]FP-CIT-SPECT, [18F]FDG PET and [123I]MIBG molecular imaging to support diagnostic procedures. Structural imaging techniques have an essential role for excluding structural causes, which could lead to a DLB-like phenotype, as well as aiding differential diagnosis through illustrating disease-specific patterns of atrophy. Novel PET molecular imaging modalities, such as amyloid and tau imaging, may provide further insights into DLB pathophysiology and may aid in early diagnosis. A multimodal approach, through combining various established techniques and possibly using novel radioligands, might further aid towards an in-depth understanding of this highly disabling disease. In this review, we will provide an overview of neuroimaging applications in patients with DLB.

Original languageEnglish
Pages (from-to)1-26
JournalJournal of Neurology
Early online date14 May 2018
Publication statusE-pub ahead of print - 14 May 2018


Dive into the research topics of 'Neuroimaging in Lewy body dementia'. Together they form a unique fingerprint.

Cite this